Voy

What Voy does

Voy is a London-headquartered digital health company that operates a doctor-led GLP-1 weight-loss platform combining prescription medication, endocrinologist consultations, behavioural coaching and connected hardware, primarily targeting adults with a BMI above 27 in markets with limited access to medically supervised obesity therapy. The company was founded in 2018 by George Pallis and operates across the United Kingdom, Germany, Brazil and, since May 2026, India (entered through the acquisition of EarlyFit, which was rebranded as Voy India). Clinical leadership includes a 20+ endocrinologist and obesity-specialist panel in India (AIIMS, Apollo, Army Hospital alumni), a Chief Medical Officer (Dr. Earim Chaudry), a separate CMO for Germany (Dr. Sarah Bechstein) and a clinical advisory bench drawn from Imperial College London, Oxford, Cambridge, Harvard, UCL and others.

The platform's product stack pairs a mobile app (4.8 App Store rating across 4.2k reviews) with an online BMI-based eligibility assessment, structured dose-titrated GLP-1 protocols (1-, 4- and 6-month plans), an integrated Voy Smart Scale tracking 14+ body vitals, an at-home full-body lab test, certified cold-chain medication delivery through third-party pharmacies, and a money-back guarantee tied to 10% body-weight loss on the 6-month plan. Outcomes cited include 21% average weight loss, 95% muscle-mass retention, a 2.4% average HbA1c drop and a clinical incident rate under 0.2% versus an approximately 4% standard of care, supported by a peer-reviewed study on 125,000 patients and an Imperial College London study on 57,975 Voy participants. AI is used for the front-end health assessment and personalization layer but is not the core differentiator.

Voy monetizes through tiered subscription programs (₹3,999 / ₹14,999 / ₹26,999), one-time hardware sales (Voy Smart Scale, ₹999), at-home diagnostic add-ons (₹999) and endocrinologist video consultations (₹499, discounted from ₹1,499). The go-to-market is product-led growth anchored on a free online weight-loss assessment, with heavy PR and earned-media amplification in Indian tier-1 outlets, organic and paid social, video content and a Trustpilot-backed reputation signal (4.7 across 18,000+ reviews). Distribution is exclusively direct-to-consumer through joinvoy.in, the Voy India mobile app, inside-sales video consultations and certified partner pharmacies for fulfillment, with no public-facing API or partner channel. Recent strategic moves include the $120M General Catalyst round (November 2025), the acquisitions of FORMEL Skin (December 2025), MoreLife (December 2025) and EarlyFit (May 2026), and the launch of the Voy Women's Health sub-brand.

Name

Voy

Legal name

Voy

Website

https://joinvoy.in

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Voy is a London-headquartered digital health platform that delivers medically supervised GLP-1 weight-loss programs, pairing prescription therapy, endocrinologist consultations, coaching, smart-scale tracking and at-home lab diagnostics for adults with elevated BMI across the UK, Germany, Brazil and India.

Ownership category

akta.pro rank

Product category

Digital Obesity Care

NAICS

Diet and Weight Reducing Centers (812191)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Obesity Medicine & Weight Management (HLAKADAL)

Keywords

• Obesity management platform
• GLP-1 weight loss
• Digital telehealth services
• Behavioral health coaching
• Endocrinologist consultations

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

1. GLP-1 weight-loss program subscriptions: Recurring revenue from tiered GLP-1 treatment plans (1-month ₹3,999; 4-month ₹14,999; 6-month ₹26,999). Medication is bundled into the program fee and fulfilled by third-party pharmacies. The 6-month plan carries the headline money-back guarantee.
2. Smart-scale hardware add-on sales: One-time sale of the Voy Smart Scale (₹999) that tracks 14+ body vitals and integrates with the app.
3. At-home lab test add-on sales: One-time sale of an at-home full-body lab test (₹999) bundled as an optional program add-on.
4. Endocrinologist consultation fees: One-time consultation fee of ₹499 (discounted from ₹1,499) for a video consultation with a Voy endocrinologist.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Core offering

Voy operates a doctor-led digital obesity-care platform that sells medically supervised GLP-1 weight-loss programs as tiered subscriptions (1-month, 4-month and 6-month plans), bundling dose-titrated GLP-1 medication, endocrinologist consultations, behavioral coaching, a mobile app, a connected smart scale, at-home lab diagnostics and cold-chain medication delivery. The flagship 6-month plan carries a 10%-of-body-weight-in-6-months money-back guarantee and is supported by clinical evidence from Imperial College London and other research collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

• Voy GLP-1 Weight Loss Program Medically supervised GLP-1 weight-loss subscription program bundling dose-titrated GLP-1 medication (4 doses of 0.25 mg escalating to 1.7 mg over 16 doses), endocrinologist oversight, AI-driven assessment, behavioral coaching, mobile-app tracking, smart-scale integration and at-home lab diagnostics. Sold in tiered 1-month (₹3,999), 4-month (₹14,999) and 6-month (₹26,999) plans, with the 6-month plan carrying a 10%-of-body-weight-in-6-months money-back guarantee.
• Voy Smart Scale

Quantifiable outcome

• 21% average weight loss among Voy users
• +8 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Partnerships

Ten partnerships are on record, tiered flagship and core.

• Imperial College LondonflagshipStrategic or Co-development PartnerResearch collaborator on a clinical study of 57,975 VOY participants that underpins Voy's outcomes messaging. Imperial's logo is featured on the About page alongside other partner institutions.
• University of OxfordcoreStrategic or Co-development PartnerListed research partner on the Voy About page; logo featured among the educational and research institutions Voy collaborates with.
• University of BirminghamcoreStrategic or Co-development PartnerListed research partner on the Voy About page; logo featured among the educational and research institutions Voy collaborates with.
• Federal University of Minas GeraiscoreStrategic or Co-development PartnerBrazilian research partner listed on the Voy About page; supports Voy's Brazilian operations and clinical research.
• Ulster UniversitycoreStrategic or Co-development PartnerListed research partner on the Voy About page; logo featured among the educational and research institutions Voy collaborates with.
• University of HertfordshirecoreStrategic or Co-development PartnerListed research partner on the Voy About page; logo featured among the educational and research institutions Voy collaborates with.
• University of CambridgecoreStrategic or Co-development PartnerReferenced in the Voy India press release as one of the research institutions Voy collaborates with on clinical studies.
• Harvard UniversitycoreStrategic or Co-development PartnerReferenced in the Voy India press release as one of the research institutions Voy collaborates with; Voy also highlights an affiliation with Harvard Medical School's Dr. Ben Reis.
• UCL (University College London)coreStrategic or Co-development PartnerReferenced in the Voy India press release as one of the research institutions Voy collaborates with on clinical studies.
• EarlyFitflagshipStrategic or Co-development PartnerIndian weight-management platform acquired by Voy and rebranded as Voy India; the founding team of Parth Chopra and Saloni Paliwal became part of the Voy India leadership. The acquisition gave Voy an immediate Indian user base, clinical network and brand presence.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Others

• Zocdoc: Online marketplace connecting patients with doctors for in-person and virtual visits. Comparable to Voy on the doctor-discovery and telehealth-appointment layer that underpins Voy's endocrinologist consultation funnel.
• Lemonade Health (Eden Health): Digital-first primary care provider combining telehealth, in-person care and chronic-condition management. Adjacent to Voy on integrating clinician-led care with digital tools for chronic metabolic and weight conditions.

Emerging players

• LifeMD: US telehealth company selling prescription weight-loss treatments, hormones and primary care via subscription. Comparable to Voy on D2C prescription weight-loss, subscription revenue model and multi-condition expansion strategy.
• Calibrate: Telehealth metabolic-care company combining GLP-1 prescriptions with coaching and tracking, focused on the US market. Comparable to Voy on integrated medical-plus-coaching GLP-1 programs and outcome-linked messaging.

Direct peers

• Ro: D2C digital health platform offering telehealth consultations, prescriptions and at-home diagnostics across multiple conditions. Closely comparable to Voy's bundled doctor + diagnostics + medication subscription model.
• Noom: Subscription weight-management app that has expanded into GLP-1 care with virtual coaching and clinician oversight. Directly competes with Voy on digital weight loss, coaching-led outcomes and consumer subscription pricing.
• Hims & Hers Health: US-listed D2C telehealth platform selling prescription weight-loss treatments (including GLP-1s) plus connected care. Directly comparable to Voy on product category, telehealth-plus-medication model and outcome-driven subscription pricing.

Regional players

• Zava: European D2C telehealth provider offering online consultations and prescription treatments across the UK, Germany, France and Ireland. Comparable to Voy on cross-border European DTC telehealth model and direct prescription fulfilment.
• Livi (Kry): Major European digital-health and telehealth operator (Kry/Livi) active in the UK, Germany, France and Scandinavia. Comparable to Voy on European GP-led telehealth infrastructure and chronic-care digital services.

Broad incumbents

• WeightWatchers (WW): Established weight-management incumbent that has expanded into GLP-1 telehealth via its Sequence acquisition. Overlaps with Voy on weight-loss subscriptions, coaching and clinician-led programs, but at much larger global scale and incumbent brand strength.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Joinvoyindia
• LinkedInlinkedin.com/company/joinvoy

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voy